BioSpace News Archive

Drug Development

IntelGenx Initiates Phase IIA Montelukast Versafilm Clinical Trial in Alzheimer’s Patients

Patient screening is expected to begin before the end of Q1 2018.

January 24, 2018
·
5 min read
Policy

Santhera Anticipates Receiving a Negative CHMP Opinion on Appeal for Marketing Authorization Application for Raxone in Duchenne Muscular Dystrophy

Santhera will provide further update on Friday, January 26, as originally announced.

January 24, 2018
·
2 min read
Pharm Country

Exalenz Bioscience Announces Positive Clinical Trial Results For the Diagnosis of Clinically Significant Portal Hypertension in NASH Patients

The BreathID platform showed positive clinical trial results in detecting CSPH in non-alcoholic steatohepatitis NASH patients with compensated advanced chronic liver disease cACLD.

January 24, 2018
·
5 min read
Business

labfolder Release: Go for Quality: New Center for Biohybrid Medical Systems at RWTH Aachen University Embarks on Digital Data Management

The new center, which will employ about 150 people, will not only provide a new building infrastructure, but also a digital infrastructure from day one.

January 24, 2018
·
5 min read
BioForest

Cocrystal Pharma Provides Update on Reverse Stock Split

The reverse stock split will be effective with the opening of trading on the OTCQB Market on Wednesday, January 24, 2018.

January 24, 2018
·
4 min read
Drug Development

Glenmark Pharma Presents Preliminary Biomarker Data on GBR 1302, a HER2xCD3 Bispecific Monoclonal Antibody, at the ASCO-SITC Clinical Immuno-Oncology Symposium

Glenmark Pharma today announced a presentation of preliminary biomarker findings from a Phase 1 study of GBR 1302.

January 24, 2018
·
3 min read
Publishing of Orion Corporation’s Financial Statement Release for 2017 on 7 February 2018

The release and related presentation material in Finnish and in English will be available on the Group’s homepage at www.orion.fi/investors promptly after the publishing.

January 24, 2018
·
1 min read
Pharm Country

Insmed Announces Pricing of Public Offering of Convertible Senior Notes

Insmed has granted the underwriters a 30-day option to purchase up to an additional $50 million in aggregate principal amount of the notes, solely to cover over-allotments.

January 24, 2018
·
10 min read
Business

Sanofi: Availability of the Pre-quarterly Results Communication - Jan. 24, 2018

Each quarter, Sanofi prepares this document to assist in the financial modeling of the Group’s quarterly results.

January 24, 2018
·
3 min read
Policy

FDA Has Approved Faron’s Traumakine IND

The FDA has already proposed that Faron can proceed directly to BLA pending positive results from the two on-going Phase III trials

January 24, 2018
·
3 min read